Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.

Experimental biology and medicine (Maywood, N.J.) - 1 Jan 2021

Li Ruichun, Chen Wei, Mao Ping, Wang Jia, Jing Jiangpeng, Sun Qinli, Wang Maode, Yu Xiao

Abstract excerpt

Temozolomide (TMZ) is the major chemotherapy agent in glioma, and isocitrate dehydrogenase (IDH) is a well-known prognostic marker in glioma. O6-methylguanine-DNA methyltransferase promoter methylation (MGMTmethyl) is a predictive biomarker in overall gliomas rather than in IDH mutant gliomas. To discover effective biomarkers that could predict TMZ efficacy in IDH mutant low-grade gliomas (LGGs), we retrieved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Sequence Annotation

Share to Multivariate Analysis

Share to Neoplasm Grading

Share to Proportional Hazards Models

Share to RNA, Untranslated

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 33028081
DOI: 10.1177/1535370220962715
PMCID: PMC7871116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.PMID 33028081Read ↗

A gene signature predicting prognosis of patients with low- grade gliomas receiving temozolomide therapySemantic proximity Read ↗

A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.Semantic proximity Read ↗

A novel DNA damage and repair-related gene signature to improve predictive capacity of overall survival for patients with gliomas.Semantic proximity Read ↗

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct PrognosesSemantic proximity Read ↗

Identification and Validation of RNA Methylation-Related Related Alternative Splicing Gene Signature for Low Grade Glioma to Predict Survival and Immune LandscapesSemantic proximity Read ↗

Mitochondrial RNA modification-based signature to predict prognosis of lower grade glioma: a multi-omics exploration and verification studySemantic proximity Read ↗

Clinicopathological signature and prognostic value of RNA:m5C methyltransferases in gliomasSemantic proximity Read ↗

Predicting temozolomide response in low-grade glioma patients with large-scale machine learningSemantic proximity Read ↗

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to TemozolomideSemantic proximity Read ↗

Identification of N6-Methyladenosine-Related Gene Based Prognostic Signature to Predict Survival and Potential Therapeutic Drugs in GliomaSemantic proximity Read ↗

Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.Semantic proximity Read ↗

Integrated single-cell and bulk RNA-sequencing data reveal prognosis and therapeutic response in low-grade glioma based on hypoxia-lactylation related genesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.